Eric Daar, MD
Enriched profileChief of the Division of HIV Medicine, Harbor-UCLA Medical Center · The Lundquist Institute at Harbor-UCLA Medical Center
Eric Daar is Chief of the Division of HIV Medicine, Harbor-UCLA Medical Center at The Lundquist Institute at Harbor-UCLA Medical Center. OpenAlex indexes 466 publications with 19,218 citations (h-index 69); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Infectious Disease profiles in the findmyKOL directory.
Data verified 21 Oct 2026
Overview
Updated 22 Oct 2026
Eric Daar, M.D., is Chief of the Division of HIV Medicine, Harbor-UCLA Medical Center at The Lundquist Institute at Harbor-UCLA Medical Center. The public record shows 466 publications with 19,218 citations (h-index 69), centered on HIV Research and Treatment, HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 10 companies, 3 NIH-funded awards (1998–2026).
- Most recent indexed publication: 2026 · Clinical infectious diseases
- Top research focus: HIV Research and Treatment
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 22 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 233.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 22 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Menopausal HT for Women Living With HIV (HoT)
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- An Integrated Intervention Using a Pill Ingestible Sensor System
Sponsor: University of California, Los Angeles
- A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
Sponsor: University of California, San Diego
Industry payments
Updated 22 Oct 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20257 payments
- Merck Sharp & Dohme LLCProgram year202521 payments
- Shionogi IncProgram year202510 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Opioid Agonist100%Hydrocodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 22 Oct 2026
3 NIH research awards on record, funded 1998–2026 per NIH RePORTER. The latest:
- An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH
University of California Los Angeles
FY2026$1,144,920R01MD019188 - An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH
University of California Los Angeles
FY2025$1,138,343R01MD019188 - An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH
University of California Los Angeles
FY2024$1,151,751R01MD019188
Publications
Updated 22 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.
Clinical infectious diseases
Guideline2026 - 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.
Clinical infectious diseases
Guideline2026 - 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.
Clinical infectious diseases
Guideline2026 - 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.
Clinical infectious diseases
Guideline2026 - Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.
Clinical infectious diseases
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Antiretroviral-Drug Resistance among Patients Recently Infected with HIVArticle1,140 citations2002
- 02Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenArticle903 citations2021
- 03
- 05Modeling Plasma Virus Concentration during Primary HIV InfectionArticle487 citations2000
Network
Updated 22 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 22 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/eric-daar-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 22 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lundquist.org ↗
Editorial & leadership roles
journal and society appointments- Member
Health and Human Services Panel for Adult and Adolescent HIV Treatment Guidelines
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lundquist.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lundquist.org ↗
- Chair
Antiretroviral Therapy Strategies Subcommittee, AIDS Clinical Trials Group
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lundquist.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
David Geffen School of Medicine at UCLA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lundquist.org ↗ - Executive Medical Officer
The Lundquist Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lundquist.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital